ABSTRACT:
We examined the activity of CB-181963, a novel cephalosporin, against methicillin-resistant
Staphylococcus aureus
(MRSA) (
n
= 200), methicillin-susceptible
S. aureus
(MSSA) (
n
= 50), glycopeptide-intermediate
Staphylococcus
species (GISS) (
n
= 47), and VRSA (
n
= 2) isolates. CB-181963 exhibited MIC profiles similar to those of linezolid against MRSA and GISS; however, activity against MSSA was similar to that of vancomycin. Time-kill study results of investigations of activity against MRSA, MSSA, and GISS at 24 h were as follows: CB-181963 activity = vancomycin activity > linezolid activity (
P
< 0.001); CB-181963 = quinupristin-dalfopristin = vancomycin > linezolid (
P
< 0.05); CB-181963 > linezolid (
P
= 0.003); and CB-181963 = quinupristin-dalfopristin = vancomycin. CB-181963 may provide an alternative treatment for multidrug-resistant staphylococci.